Short-term escitalopram treatment normalizes aberrant self-referential processing in major depressive disorder

被引:22
作者
Komulainen, Emma [1 ,2 ]
Heikkila, Roope [1 ,2 ]
Nummenmaa, Lauri [3 ,4 ]
Raij, Tuukka T. [1 ,2 ,5 ,6 ]
Harmer, Catherine J. [7 ]
Isometsa, Erkki [1 ,2 ]
Ekelund, Jesper [8 ,9 ]
机构
[1] Univ Helsinki, Helsinki, Finland
[2] Helsinki Univ Hosp, Psychiat, Helsinki, Finland
[3] Univ Turku, Turku PET Ctr, Turku, Finland
[4] Univ Turku, Dept Psychol, Turku, Finland
[5] Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, Espoo, Finland
[6] Aalto Univ, Aalto NeuroImaging, Espoo, Finland
[7] Univ Dept Psychiat, Oxford, England
[8] Univ Turku, Turku, Finland
[9] Turku Univ Hosp, Turku, Finland
基金
芬兰科学院;
关键词
Depression; Antidepressant; Escitalopram; fMRI; Emotion; Self-referential processing; MEDIAL PREFRONTAL CORTEX; DEFAULT-MODE NETWORK; HEALTHY-VOLUNTEERS; BRAIN; METAANALYSIS; RECOGNITION; INVENTORY; RESPONSES; BIAS; MRI;
D O I
10.1016/j.jad.2018.04.096
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Increased self-focus and negative self-concept play an important role in depression. Antidepressants influence self-referential processing in healthy volunteers, but their function in self-processing of depressed patients remains unknown. Methods: Thirty-two depressed patients were randomly allocated to receive either escitalopram 10 mg or placebo for one week. After one week, neural responses to positive and negative self-referential adjectives and neutral control stimuli were assessed with functional magnetic resonance imaging. A group of matched healthy volunteers served as a control group. Results: Escitalopram decreased responses of medial fronto-parietal regions to self-referential words relative to non-emotional control stimuli, driven by increased responses to the control condition. Escitalopram also increased responses in the pre-defined region of the medial prefrontal cortex (MPFC) and the anterior cingulate cortex (ACC) to positive relative to negative words. Importantly, the changes in neural responses occurred before any effect on depressive symptoms, implying a direct effect of escitalopram. Furthermore, the placebo group had decreased responses of the MPFC and the ACC to positive self-referential processing relative to the matched healthy controls. However, neural responses of the escitalopram group and the healthy unmedicated controls were similar. Limitations: Differences between the groups in self-reported depression symptoms and personality traits may have influenced the results. Conclusion: One-week treatment with escitalopram normalized aberrant self-referential processing in depressed patients, shifting the focus from the self to the external environment and potentiating positive self-referential processing. This may be an important factor in mechanism of action of antidepressants.
引用
收藏
页码:222 / 229
页数:8
相关论文
共 50 条
  • [41] Effect of short-term antidepressant treatment on early maladaptive schemas in patients with major depressive and panic disorder
    Atalay, Hakan
    Atalay, Figen
    Bagdacicek, Sedat
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2011, 15 (02) : 97 - 105
  • [42] Frontoparietal and Default Mode Network Contributions to Self-Referential Processing in Social Anxiety Disorder
    Matthew L. Dixon
    Craig A. Moodie
    Philippe R. Goldin
    Norman Farb
    Richard G. Heimberg
    Jinxiao Zhang
    James J. Gross
    Cognitive, Affective, & Behavioral Neuroscience, 2022, 22 : 187 - 198
  • [43] Neurocognitive Heterogeneity in Social Anxiety Disorder: The Role of Self-Referential Processing and Childhood Maltreatment
    Talmon, Anat
    Dixon, Matthew Luke
    Goldin, Philippe R.
    Heimberg, Richard G.
    Gross, James J.
    CLINICAL PSYCHOLOGICAL SCIENCE, 2021, 9 (06) : 1045 - 1058
  • [44] Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder
    Jarcuskova, Dominika
    Tkac, Ivan
    Hlavacova, Natasa
    Yaluri, Alena Stancakova
    Kozarova, Miriam
    Habalova, Viera
    Klimcakova, Lucia
    Zidzik, Jozef
    Javorsky, Martin
    Bednarova, Aneta
    BMC PSYCHIATRY, 2024, 24 (01)
  • [45] Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder
    Kennedy, Sidney H.
    Grouin, Jean-Marie
    Cadour, Stephanie
    Robert, Veronique
    Picarel-Blanchot, Francoise
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2018, 33 (01)
  • [46] A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder
    Armstrong, Edward P.
    Malone, Daniel C.
    Erder, M. Haim
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (04) : 1115 - 1121
  • [47] Therapeutic effects of short-term trauma stabilization techniques combined with escitalopram in treating adolescent major depressive disorder: a pilot randomised controlled trial
    Xu, Jiating
    Wu, Jiajia
    Wang, Xiaojing
    Chen, Qianqian
    Xu, Ruizhi
    Xu, Yaoyan
    Geng, Xiuchao
    Tang, Yiping
    BMC PSYCHIATRY, 2025, 25 (01)
  • [48] Trait and state abnormalities in automatic and strategic processing during self-referential encoding in major depression
    Shestyuk, Avgusta Y.
    Deldin, Patricia J.
    PSYCHOPHYSIOLOGY, 2006, 43 : S89 - S90
  • [49] Self-referential processing during observation of a speech performance task in social anxiety disorder from pre- to post-treatment: Evidence of disrupted neural activation
    Brown, Lily A.
    Young, Katherine S.
    Goldin, Philippe R.
    Torre, Jared B.
    Burklund, Lisa J.
    Davies, Carolyn D.
    Niles, Andrea N.
    Lieberman, Matthew D.
    Saxbe, Darby E.
    Craske, Michelle G.
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2019, 284 : 13 - 20
  • [50] Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
    Weiss, Brandon
    Roseman, Leor
    Giribaldi, Bruna
    Nutt, David J.
    Carhart-Harris, Robin L.
    Erritzoe, David
    INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION, 2024, 22 (02) : 806 - 841